Cullin 7 Polyklonale Antilichaam, HRP-vervoeging

Component of a probable SCF-like E3 ubiquitin-protein ligase complex, which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably plays a role in the degradation of proteins involved in endothelial proliferation and/or differentiation (By similarity) . Seems not to promote polyubiquitination and proteasomal degradation of TP53. In vitro, complexes of CUL7 with either CUL9 or FBXW8 or TP53 contain E3 ubiquitin-protein ligase activity.Involvement in disease: Defects in CUL7 are the cause of 3M syndrome type 1 (3M1) . An autosomal recessive disorder characterized by severe pre- and postnatal growth retardation, facial dysmorphism, large head circumference, and normal intelligence and endocrine function. Skeletal changes include long slender tubular bones and tall vertebral bodies.

CUL-7; CUL7; CUL7_HUMAN; Cullin-7; dJ20C7.5; KIAA0076.

9820

Human, Mouse, Rat

1251-1400/1698

Cullin 7

HRP

KLH conjugated synthetic peptide derived from human Cullin 7

WB, ELISA, IHC-P, IHC-F

Purified by Protein A.

1µg/µl

WB (WB=1:500-2000), ELISA (ELISA=1:5000-10000), IHC-P (IHC-P=1:100-500), IHC-F (IHC-F=1:100-500)

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

9820